Antifungal Treatment Market To Grow Substantially At A CAGR Of 3.80% From 2024 To 2033

Trisha Jadhav
4 min readMay 27, 2024

--

As per the current market research conducted by the CMI Team, the global Antifungal Treatment Market size is expected to record a CAGR of 3.8% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 18,813.2 Million. By 2033, the valuation is anticipated to reach USD 26,317.2 Million.

Antifungal Treatment Market: Growth Factors and Dynamics

  • Rising Incidence of Fungal Infections: The increasing prevalence of fungal infections, particularly among immunocompromised individuals such as HIV/AIDS patients, organ transplant recipients, and chemotherapy patients, is a significant driver of market growth.
  • Advancements in Antifungal Therapeutics: Ongoing research and development efforts have led to the introduction of novel antifungal agents with improved efficacy, safety profiles, and modes of administration, driving market expansion.
  • Growing Awareness and Diagnosis: Enhanced awareness among healthcare professionals and patients regarding the diagnosis and treatment of fungal infections has led to early detection and prompt initiation of antifungal therapy, contributing to market growth.
  • Expanding Geriatric Population: The aging population, coupled with a higher prevalence of chronic diseases and weakened immune systems among the elderly, has resulted in a higher incidence of fungal infections, fueling the demand for antifungal treatments.
  • Increase in Antifungal Resistance: The emergence of antifungal-resistant strains, such as Candida auris, poses a significant challenge to current treatment modalities, driving the need for innovative antifungal agents and alternative treatment strategies.
  • Healthcare Infrastructure Development: Improvements in healthcare infrastructure, particularly in developing regions, along with increased access to antifungal medications and diagnostic tools, are fostering market growth by addressing unmet medical needs and expanding the patient pool for antifungal treatment.
  • Changing Demographics and Lifestyles: Shifts in demographics, such as urbanization, lifestyle changes, and increased travel, contribute to the spread of fungal infections. Factors like poor hygiene, climate change, and the use of immunosuppressive medications also play a role in the rising incidence of fungal diseases, thereby driving demand for antifungal treatments.
  • Regulatory Support and Funding Initiatives: Supportive regulatory frameworks and funding initiatives from government bodies and healthcare organizations encourage research and development in antifungal therapeutics. Regulatory approvals, incentives for orphan drug development, and grants for clinical trials stimulate innovation in the field, fostering market growth and facilitating the introduction of new antifungal treatments to the market.
  • Supply Chain Optimization: Efforts to optimize supply chains, ensure adequate stock levels of antifungal medications, and enhance distribution networks can help mitigate disruptions and ensure the availability of treatments, supporting the recovery of the antifungal treatment market. Collaboration between pharmaceutical companies, regulatory authorities, and logistics providers may facilitate the efficient delivery of antifungal drugs to healthcare facilities and patients in need.

Get Free Sample Copy @ https://www.custommarketinsights.com/request-for-free-sample/?reportid=49352

Antifungal Treatment Market: Partnership and Acquisitions

  • In 2023, Basilea Pharmaceutica acquired rights to fosmanogepix, a broad-spectrum antifungal, through a partnership with Amplyx Pharmaceuticals. This strategic acquisition bolsters Basilea’s clinical antifungal pipeline, paving the way for phase 3 studies and enhancing its position in the antifungal market.
  • In 2022, The US FDA approved VIVJOA (oteseconazole capsules), the first FDA-approved medication from Mycovia Pharmaceuticals, Inc., indicated to reduce recurrent vulvovaginal candidiasis (RVVC) in females. This azole antifungal represents a significant milestone for both Mycovia and the treatment of RVVC.

Antifungal Treatment Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the Antifungal Treatment Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

  • Increased Risk of Fungal Infections: COVID-19 patients, particularly those with severe illness or prolonged hospitalization, are at increased risk of developing fungal infections such as invasive candidiasis or aspergillosis, leading to higher demand for antifungal treatments.
  • Disruption of Healthcare Services: The diversion of healthcare resources, overwhelmed healthcare systems, and disruptions in routine medical care during the pandemic may have led to delayed diagnosis and treatment of fungal infections, impacting the demand for antifungal treatments.
  • Resumption of Healthcare Services: As healthcare systems stabilize and pandemic-related restrictions ease, there will likely be a resumption of routine medical care, including diagnosis and treatment of fungal infections, contributing to the recovery of the antifungal treatment market.

List of the prominent players in the Antifungal Treatment Market:

  • Pfizer Inc.
  • Novartis AG
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Bayer AG
  • Sanofi
  • AbbVie Inc.
  • Eli Lilly and Company
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol Myers Squibb Company
  • Valeant Pharmaceuticals International Inc.
  • Basilea Pharmaceutica AG
  • Others

Table of Contents: https://www.custommarketinsights.com/report/antifungal-treatment-market/#table-of-contents

About Us:

Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains.

Custom Market Insights provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey.

Contact Us:

USA Corporate Office

CMI Consulting LLC

1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702
Sales & Support +1 801 639 9061

Email : support@custommarketinsights.com

Website : https://www.custommarketinsights.com/

--

--